Q-omics provides the consensus-scored RNA5SP310 profile across patient tissues and cancer cell-line models. RNA5SP310 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, RNA5SP310 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RNA5SP310 RNA expression shows 8,865 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight TGCT, KIRC, and ESCA as cancer lineages where RNA5SP310 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP310 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP310 survival associations across molecular data types. RNA5SP310 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP310 RNA expression–survival associations across cancer types. High RNA5SP310 expression shows unfavorable associations in TGCT, THCA, LIHC, KICH and COAD, but favorable associations in LAML. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify TGCT as the clearest survival context for RNA5SP310 RNA expression.
This table summarizes RNA5SP310 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP310. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP310 shows lower tumor expression in KIRC and higher tumor expression in KICH and KIRP. The KIRC box plot shows higher RNA5SP310 RNA expression in normal versus tumor tissue (log2 FC = −0.142, t-test p = .002).
This table shows molecular features associated with RNA5SP310 in patient tissues and cancer cell lines. In patient samples, RNA5SP310 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
